Improved postprandial glucose control using the insu pad device in insulin-treated type 2 diabetes: Injection site warming to improve glycemic contro

Journal of Diabetes Science and Technology

Volumn 9, Issue 3, 2015, Pages 639-643

  Raz, Itamar ^a   Bitton, Gabriel ^b   Feldman, Dmitry ^b   Alon, Tal ^b   Pfutzner, Andreas ^c,d   Tamborlane, William V ^e  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b InsuLine Medical Ltd   (Israel)

^c Diabetes Center and Practice   (Germany)

^d Pfutzner Science and Health Institute   (Germany)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glucose control; Hyperglycemia; Postprandial; Warming device

Indexed keywords

INSULIN ASPART; INSULIN LISPRO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BOLUS INJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; FEMALE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; INJECTION SITE; INJECTION SITE WARMING; INSULIN TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MEAL TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SKIN WARMING DEVICE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; WARMING; ADOLESCENT; AGED; BLOOD; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN INFUSION; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TEMPERATURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TEMPERATURE; YOUNG ADULT;

EID: 84942322499     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815578881     Document Type: Article

References (18)

1. Satish KG. New insulin analogues. Diabetes Technol Ther. 2005;7:813-817.
2. Becker R, Frick A, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care. 2007;30:2506-2507.
3. Walsh J, Roberts R, Heinemann L. Confusion regarding duration of insulin action: A potential source for major insulin dose errors by bolus calculators. J Diabetes Sci Technol. 2014;8:170-178.
4. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682.
5. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92(1):59-61.
6. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J. 1980;280: 1411-1413.
7. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose phar-macokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009; 31:980-987.
8. Freckmann G, Pleus S, Westhoff A, et al. Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study. J Diabetes Sci Technol. 2012;6:320-327.
9. Freckmann G, Pleus S, Haug C, Bitton G, Nagar R. Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions. J Diabetes Sci Technol. 2012;6:780-785.
10. Cengiz E, Weinzimer SA, Sherr JL, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabetes. 2013;14:168-173.
11. Pfützner A, Hermanns N, Funke K, et al. The BARMER Study: impact of standardized warming of the injections-site to enhance insulin absorption and to reduce insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 2014;30:753-760.
12. Heinemann L, Muchmore DB. Ultrafast acting insulins: state of the art. J Diabetes Sci Technol. 2012;6:728-742.
13. McVey E, Hirsch L, Sutter DE, et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol. 2012;6:743-754.
14. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care. 2011;34:1804-1808.
15. Edsberg B, Herly D, Hildebrandt P, Kühl C. Insulin bolus given by sprinkler needle: effect on absorption and glycaemic response to a meal. Br Med J. 1987;294:1373-1376.
16. Heinemann L, Hompesch M, Flacke F, et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol. 2011;5:681-686.
17. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol. 2012;6:764-772.
18. Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46:265-270.